INmune Bio Inc(INMB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INMB INmune Bio Inc

交易中 07-22 14:37:09 EDT

1.84

-0.13

-6.85%

最高1.98	最低1.80	成交量26.87万
今开1.98	昨收1.97	日振幅9.14%
总市值4,878万	流通市值4,067万	总股本2,659万
成交额50.16万	换手率1.21%	流通股本2,216万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INMB","market":"US","secType":"STK","nameCN":"INmune Bio Inc","latestPrice":1.835,"timestamp":1784745388415,"preClose":1.97,"halted":0,"volume":268704,"delay":0,"changeRate":-0.0685279187817259,"floatShares":22162600,"shares":26585258,"eps":-1.63,"marketStatus":"交易中","change":-0.135,"latestTime":"07-22 14:37:09 EDT","open":1.98,"high":1.98,"low":1.8,"amount":501569.4965184,"amplitude":0.091371,"askPrice":1.84,"askSize":1346,"bidPrice":1.83,"bidSize":760,"shortable":3,"etf":0,"ttmEps":-1.63,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784750400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1549256400000,"exchange":"NASDAQ","adjPreClose":1.97,"preHourTrading":{"tag":"盘前","latestPrice":1.9311,"preClose":1.97,"latestTime":"09:12 EDT","volume":13092,"amount":25440.1295796,"timestamp":1784725975146,"change":-0.0389,"changeRate":-0.019746,"amplitude":0.069848},"postHourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":1.97,"latestTime":"19:54 EDT","volume":2154,"amount":4250.44,"timestamp":1784678065166,"change":0,"changeRate":0,"amplitude":0.010102},"volumeRatio":0.511218,"impliedVol":2.0703,"impliedVolPercentile":0.8167},"requestUrl":"/m/hq/s/INMB","defaultTab":"news","newsList":[{"id":"1138493745","title":"INmune Bio达成商业化生产里程碑，为Cordstrom™平台全球注册申报铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=1138493745","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138493745?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:01","pubTimestamp":1784545278,"startTime":"0","endTime":"0","summary":"INmune Bio Inc已成功达成一项关键的商业化生产里程碑，此举为其计划中的Cordstrom™平台全球注册申报提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108598562","title":"INmune Bio旗下Xpro1595在最新同行评审临床前研究中展现潜力：可预防脑损伤诱发的阿尔茨海默病理、记忆丧失及疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=1108598562","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108598562?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:02","pubTimestamp":1784113341,"startTime":"0","endTime":"0","summary":"INmune Bio Inc 公布的最新同行评审临床前研究数据显示，其候选药物Xpro1595在预防脑损伤引发的阿尔茨海默病理、记忆功能衰退及疼痛方面展现出积极效果。该研究结果进一步揭示了Xpro1595在神经退行性疾病领域的潜在治疗价值。实验表明，该药物能够有效阻断由脑损伤触发的特定病理进程，从而防止与阿尔茨海默病相关的标志性病变形成。这些发现为Xpro1595的后续开发提供了重要的临床前依据，并可能为创伤性脑损伤后神经退行性并发症的预防和治疗开辟新的途径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117980652","title":"INmune Bio推进最终商业化生产验证活动及档案汇编，以支持计划的英国提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1117980652","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117980652?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:07","pubTimestamp":1782216436,"startTime":"0","endTime":"0","summary":"INmune Bio Inc正在推进其最终商业化生产的验证活动，并同步进行相关档案的汇编工作，旨在支持其计划向英国监管机构提交的申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155908475","title":"INmune Bio获MHRA书面支持，计划2026年在英国提交Cordstrom™治疗RDEB的有条件上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1155908475","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155908475?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:02","pubTimestamp":1782216175,"startTime":"0","endTime":"0","summary":"INmune Bio公司宣布，已获得英国药品和保健品监管局的书面支持，这为其计划在2026年提交Cordstrom用于治疗隐性营养不良型大疱性表皮松解症的有条件上市许可申请铺平了道路。Cordstrom是INmune Bio正在开发的一款针对RDEB这种严重罕见皮肤病的研究性疗法。Cordstrom若最终获得有条件上市许可，将为患者提供一个重要的潜在治疗选择。INmune Bio将继续推进相关临床开发工作，以期在计划时间内完成申请提交。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151842008","title":"INmune Bio旗下Xpro1595在炎症水平升高且生物标志物富集的患者中疗效增强","url":"https://stock-news.laohu8.com/highlight/detail?id=1151842008","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151842008?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:05","pubTimestamp":1780401957,"startTime":"0","endTime":"0","summary":"INmune Bio公司宣布，其研发的药物Xpro1595在针对炎症水平升高且生物标志物富集的患者群体中，展现出更为显著的疗效。这一发现基于最新的临床数据分析，突显了精准医疗在神经退行性疾病治疗领域的潜力。通过筛选特定生物标志物，研究团队能够更准确地识别出对治疗反应更佳的患者，从而优化临床试验设计并提升治疗成功率。该进展为INmune Bio的未来临床开发策略提供了关键依据，并有望加速相关疗法的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135204303","title":"INmune Bio公布二期Mindful阿尔茨海默病试验结果：先进白质MRI生物标志物显示具有统计学意义的治疗效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1135204303","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135204303?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:01","pubTimestamp":1780401694,"startTime":"0","endTime":"0","summary":"INmune Bio公司宣布，在其针对阿尔茨海默病进行的二期Mindful临床试验中，其疗法对先进的脑白质磁共振成像生物标志物产生了统计学意义上显著的治疗效果。该研究结果揭示了该疗法在影响疾病关键病理生理进程方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124222845","title":"INmune Bio与Anthony Nolan宣布战略扩展Cordstrom™ MSC平台合作，瞄准RDEB、肿瘤及炎症性疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1124222845","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124222845?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:00","pubTimestamp":1778011217,"startTime":"0","endTime":"0","summary":"INmune Bio Inc与Anthony Nolan共同宣布，双方将战略性地扩展基于Cordstrom™间充质干细胞（MSC）平台的研发合作。此次合作范围的扩大，旨在重点攻克罕见皮肤病隐性营养不良型大疱性表皮松解症（RDEB）、多种肿瘤以及一系列炎症性疾病的治疗难题。通过深化这一平台合作，双方期望加速开发创新疗法，为存在高度未满足医疗需求的疾病领域提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177618794","title":"INmune Bio Inc. 将于5月7日周四公布2026年第一季度财报并举行业务更新会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1177618794","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177618794?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:01","pubTimestamp":1777550503,"startTime":"0","endTime":"0","summary":"生物技术公司INmune Bio Inc. (INMB) 计划于5月7日周四发布其2026年第一季度的财务业绩报告。届时，公司管理层将同步召开业务更新会议，向投资者详细介绍公司的最新运营进展和未来战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127966233","title":"INmune Bio Inc. 将于3月30日周一公布2025财年业绩并举行公司进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1127966233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127966233?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:02","pubTimestamp":1774353758,"startTime":"0","endTime":"0","summary":"生物技术公司INmune Bio Inc. (INMB) 已正式宣布，其2025财年全年财务业绩报告及公司业务最新进展的发布，定于3月30日星期一进行。此次公告将向投资者和市场全面展示公司在过去一个财年的财务健康状况，并分享其在研管线及战略规划的关键更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175796711","title":"INmune Bio的Mindful试验在Ad/Pd 2026全会上被列为靶向早期阿尔茨海默病炎症临床试验的成功范例","url":"https://stock-news.laohu8.com/highlight/detail?id=1175796711","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175796711?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:03","pubTimestamp":1773921794,"startTime":"0","endTime":"0","summary":"INmune Bio Inc的Mindful试验，在Ad/Pd 2026全会中备受瞩目，被作为如何开展针对早期阿尔茨海默病炎症的临床试验的成功典范进行展示。该试验的策略和方法获得了广泛认可，凸显了其在应对神经炎症挑战方面的创新价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618956964","title":"Inmune Bio Inc.盘中异动 股价大跌7.52%报1.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618956964","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618956964?lang=zh_cn&edition=full","pubTime":"2026-03-10 01:34","pubTimestamp":1773077646,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日01时34分，Inmune Bio Inc.股票出现异动，股价快速下挫7.52%。Inmune Bio Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，An2 Therapeutics, Inc.、Camp4 Therapeutics Corporation、Xenon制药涨幅较大，An2 Therapeutics, Inc.、Acurx Pharmaceuticals, Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为173.54%、71.29%、61.93%，振幅较大的相关个股有An2 Therapeutics, Inc.、Camp4 Therapeutics Corporation、Briacell Therapeutics Corp C/Wts ，振幅分别为138.24%、67.86%、66.47%。Inmune Bio Inc.公司简介：INmune Bio Inc 是一家临床阶段的生物技术公司。该公司的管道产品包括 INKmune、INBO3、XPro1595、LIVNate 等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310013406a45c4c9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310013406a45c4c9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613657747","title":"Inmune Bio Inc.盘中异动 股价大跌6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613657747","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613657747?lang=zh_cn&edition=full","pubTime":"2026-02-24 01:42","pubTimestamp":1771868561,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日01时42分，Inmune Bio Inc.股票出现波动，股价急速下挫6.49%。截至发稿，该股报1.23美元/股，成交量26.401万股，换手率0.99%，振幅6.48%。Inmune Bio Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Inmune Bio Inc.公司简介：INmune Bio Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022401424297a6bcba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022401424297a6bcba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612023606","title":"Inmune Bio Inc.盘中异动 大幅下跌5.19%报1.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612023606","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612023606?lang=zh_cn&edition=full","pubTime":"2026-02-19 23:58","pubTimestamp":1771516711,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日23时58分，Inmune Bio Inc.股票出现异动，股价快速下跌5.19%。截至发稿，该股报1.28美元/股，成交量8.8041万股，换手率0.33%，振幅5.59%。Inmune Bio Inc.股票所在的生物技术行业中，整体跌幅为0.54%。其相关个股中，Moolec Science Sa C/Wts 30/01/2028、Dermata Therapeutics, Inc.、Novabay Pharmaceuticals, Inc.涨幅较大，Enveric Biosciences, Inc.、Pmgc Holdings Inc.、Theriva Biologics, Inc.较为活跃，换手率分别为1181.55%、739.62%、676.65%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Cingulate Inc C/Wts 10/12/2026 ，振幅分别为247.75%、51.67%、36.40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021923583197a6854a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021923583197a6854a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152434190","title":"INmune Bio宣布与FDA就Xpro1595治疗早期阿尔茨海默病的综合2B/3期注册路径达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1152434190","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152434190?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:01","pubTimestamp":1770897683,"startTime":"0","endTime":"0","summary":"生物技术公司INmune Bio Inc. 已正式宣布，其针对早期阿尔茨海默病的在研疗法Xpro1595，获得了美国食品药品监督管理局（FDA）对其综合2B/3期注册路径的认可。这一关键进展标志着该药物的临床开发计划向前迈出了重要一步，为后续的注册申请奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610360030","title":"Inmune Bio Inc.盘中异动 早盘股价大涨5.19%报1.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610360030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610360030?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:53","pubTimestamp":1770735183,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时53分，Inmune Bio Inc.股票出现波动，股价快速拉升5.19%。截至发稿，该股报1.62美元/股，成交量2.0152万股，换手率0.08%，振幅3.25%。Inmune Bio Inc.股票所在的生物技术行业中，整体涨幅为0.38%。其相关个股中，Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.涨幅较大，Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃，换手率分别为1679.45%、764.13%、676.03%，振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Ernexa Therapeutics Inc C/Wts  04/02/2030，振幅分别为58.92%、34.87%、28.57%。Inmune Bio Inc.公司简介：INmune Bio Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210225304a6eb0789&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210225304a6eb0789&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155392638","title":"INmune Bio Inc发布股东信函：回顾2025年里程碑，勾勒2026年战略蓝图","url":"https://stock-news.laohu8.com/highlight/detail?id=1155392638","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155392638?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:25","pubTimestamp":1769523912,"startTime":"0","endTime":"0","summary":"INmune Bio Inc（股票代码：INMB）近日向股东发布了一封重要信函，详细回顾了公司在2025年取得的关键成就与里程碑事件。信函同时系统性地阐述了为2026年规划的系列战略举措与发展重点，展现了管理层对未来的清晰布局与坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517060753","title":"Inmune Bio Inc.盘中异动 急速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517060753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517060753?lang=zh_cn&edition=full","pubTime":"2025-03-05 02:22","pubTimestamp":1741112554,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日02时22分，Inmune Bio Inc.股票出现异动，股价急速上涨5.04%。截至发稿，该股报8.13美元/股，成交量10.9056万股，换手率0.49%，振幅9.04%。Inmune Bio Inc.股票所在的生物技术行业中，整体跌幅为0.24%。Inmune Bio Inc.公司简介：INmune Bio Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305022234a25f44b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305022234a25f44b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514827153","title":"Inmune Bio Inc.盘中异动 早盘股价大涨6.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514827153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514827153?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:21","pubTimestamp":1740673317,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时21分，Inmune Bio Inc.股票出现异动，股价快速拉升6.79%。截至发稿，该股报8.33美元/股，成交量4.2678万股，换手率0.19%，振幅4.10%。Inmune Bio Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Pepgen Inc.、Alpha Tau Medical Ltd C/Wts 、Heron Therapeutics, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1647.01%、264.47%、112.04%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Quoin Pharmaceuticals Ltd、Pds Biotechnology Corporation，振幅分别为86.14%、47.79%、45.45%。Inmune Bio Inc.公司简介：INmune Bio Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228002157abdf893f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228002157abdf893f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856915","title":"Inmune Bio Inc.盘中异动 早盘快速上涨5.48%报8.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856915","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514856915?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:30","pubTimestamp":1740580248,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时30分，Inmune Bio Inc.股票出现波动，股价大幅上涨5.48%。截至发稿，该股报8.08美元/股，成交量5834股，换手率0.03%，振幅0.00%。Inmune Bio Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Arcutis Biotherapeutics, Inc.涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2622.08%、109.80%、84.24%，振幅较大的相关个股有Eterna Therapeutics Inc.、Ocean Biomedical, Inc.、内克塔治疗，振幅分别为6.37%、6.00%、5.74%。Inmune Bio Inc.公司简介：INmune Bio Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223049abddec52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223049abddec52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513541720","title":"Inmune Bio Inc.盘中异动 急速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513541720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513541720?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:01","pubTimestamp":1740409301,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时01分，Inmune Bio Inc.股票出现异动，股价急速下跌5.01%。截至发稿，该股报8.16美元/股，成交量3.8679万股，换手率0.17%，振幅6.05%。Inmune Bio Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Avalo Therapeutics, Inc.涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为155.16%、68.88%、25.12%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Inmune Bio Inc.公司简介：INmune Bio Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230141962ea072&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230141962ea072&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INMB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inmunebio.com","stockEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":0.3586},{"period":"3month","weight":0.3776},{"period":"6month","weight":0.1588},{"period":"1year","weight":-0.1723},{"period":"ytd","weight":0.2628}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"INmune Bio Inc.最初于2015年9月25日在内华达州成立。该公司是一家临床阶段的生物技术公司，专注于通过重编程先天免疫系统来治疗由慢性炎症和免疫功能障碍驱动的疾病。其主要项目CORDStrom是一个用于治疗隐性营养不良性大疱性表皮松解症的间充质基质细胞平台，同时还有针对神经炎症和肿瘤学的其他研发管线。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.215238},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.09431},{"month":3,"riseRate":0.125,"avgChangeRate":-0.129323},{"month":4,"riseRate":0.75,"avgChangeRate":0.146094},{"month":5,"riseRate":0.375,"avgChangeRate":-0.010189},{"month":6,"riseRate":0.5,"avgChangeRate":0.006177},{"month":7,"riseRate":0.5,"avgChangeRate":0.166332},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.073693},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.111152},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.027835},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.015317},{"month":12,"riseRate":0.428571,"avgChangeRate":0.11764}],"exchange":"NASDAQ","name":"INmune Bio Inc","nameEN":"INmune Bio Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INmune Bio Inc(INMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供INmune Bio Inc(INMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"INmune Bio Inc,INMB,INmune Bio Inc股票,INmune Bio Inc股票老虎,INmune Bio Inc股票老虎国际,INmune Bio Inc行情,INmune Bio Inc股票行情,INmune Bio Inc股价,INmune Bio Inc股市,INmune Bio Inc股票价格,INmune Bio Inc股票交易,INmune Bio Inc股票购买,INmune Bio Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INmune Bio Inc(INMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供INmune Bio Inc(INMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}